SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center.
COVID-19
/ diagnosis
Cross Infection
/ diagnosis
Disinfection
/ methods
Environmental Monitoring
/ methods
Humans
Inpatients
/ statistics & numerical data
Neoplasms
/ diagnosis
Outpatients
/ statistics & numerical data
Prospective Studies
RNA, Viral
/ genetics
Real-Time Polymerase Chain Reaction
/ methods
SARS-CoV-2
/ genetics
Surface Properties
Tertiary Care Centers
coronavirus disease 2019 (COVID-19)
environmental surface testing
hematologic malignancies
quality improvement
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
solid tumors
viral transmission
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
revised:
06
12
2020
received:
07
08
2020
accepted:
22
12
2020
pubmed:
19
2
2021
medline:
25
5
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
Despite consensus guidelines, concern about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission has dissuaded patients with cancer from seeking medical care. Studies have shown that contaminated surfaces may contain viable virus for up to 72 hours in laboratory settings. The purpose of this study was to investigate contamination of SARS-CoV-2 on commonly used environmental surfaces in a tertiary cancer care center. This study evaluated the incidence of SARS-CoV-2 viral RNA in high-touch outpatient and inpatient cancer center spaces. Surfaces were tested over a 2-week period after patient or staff exposure but before scheduled disinfection services according to the World Health Organization protocols for coronavirus disease 2019 (COVID-19) surface sampling. Samples were analyzed via reverse transcriptase-polymerase chain reaction for the presence of SARS-CoV-2 RNA. Two hundred four environmental samples were obtained from inpatient and outpatient oncology clinics and infusion suites, and they were categorized as 1) public areas, 2) staff areas, or 3) medical equipment. One hundred thirty surfaces from 2 outpatient hematology and oncology clinics and 36 surfaces from an inpatient leukemia/lymphoma/chimeric antigen receptor T-cell unit were examined, and all 166 samples were negative for SARS-CoV-2. One of 38 samples (2.6%) from COVID-19+ inpatient units was positive. Altogether, the positive test rate for SARS-CoV-2 RNA across all surfaces was 0.5% (1 of 204). This prospective, systematic quality assurance investigation of real-world environmental surfaces, performed in inpatient and outpatient hematology/oncology units, revealed overall negligible detection of SARS-CoV-2 RNA when strict mitigation strategies against COVID-19 transmission were instituted. The potential risks of nosocomial infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have deterred patients with cancer from seeking timely care despite consensus guidelines. This study has found negligible rates of environmental contamination with SARS-CoV-2 across a multitude of commonly used surfaces in outpatient and inpatient hematology/oncology settings with adherence to strict infection control protocols.
Sections du résumé
BACKGROUND
Despite consensus guidelines, concern about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission has dissuaded patients with cancer from seeking medical care. Studies have shown that contaminated surfaces may contain viable virus for up to 72 hours in laboratory settings. The purpose of this study was to investigate contamination of SARS-CoV-2 on commonly used environmental surfaces in a tertiary cancer care center.
METHODS
This study evaluated the incidence of SARS-CoV-2 viral RNA in high-touch outpatient and inpatient cancer center spaces. Surfaces were tested over a 2-week period after patient or staff exposure but before scheduled disinfection services according to the World Health Organization protocols for coronavirus disease 2019 (COVID-19) surface sampling. Samples were analyzed via reverse transcriptase-polymerase chain reaction for the presence of SARS-CoV-2 RNA.
RESULTS
Two hundred four environmental samples were obtained from inpatient and outpatient oncology clinics and infusion suites, and they were categorized as 1) public areas, 2) staff areas, or 3) medical equipment. One hundred thirty surfaces from 2 outpatient hematology and oncology clinics and 36 surfaces from an inpatient leukemia/lymphoma/chimeric antigen receptor T-cell unit were examined, and all 166 samples were negative for SARS-CoV-2. One of 38 samples (2.6%) from COVID-19+ inpatient units was positive. Altogether, the positive test rate for SARS-CoV-2 RNA across all surfaces was 0.5% (1 of 204).
CONCLUSIONS
This prospective, systematic quality assurance investigation of real-world environmental surfaces, performed in inpatient and outpatient hematology/oncology units, revealed overall negligible detection of SARS-CoV-2 RNA when strict mitigation strategies against COVID-19 transmission were instituted.
LAY SUMMARY
The potential risks of nosocomial infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have deterred patients with cancer from seeking timely care despite consensus guidelines. This study has found negligible rates of environmental contamination with SARS-CoV-2 across a multitude of commonly used surfaces in outpatient and inpatient hematology/oncology settings with adherence to strict infection control protocols.
Identifiants
pubmed: 33599303
doi: 10.1002/cncr.33453
pmc: PMC8014051
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1926-1932Informations de copyright
© 2021 American Cancer Society.
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nature. 2020 Jun;582(7813):557-560
pubmed: 32340022
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
JCO Clin Cancer Inform. 2020 Jul;4:657-665
pubmed: 32716647
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
Nat Commun. 2020 May 29;11(1):2800
pubmed: 32472043
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32277022
J Infect. 2020 Aug;81(2):e1-e5
pubmed: 32360881
Nat Cancer. 2020 Jun;1(6):565-567
pubmed: 35121972
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Epidemiol Infect. 2020 Jul 14;148:e154
pubmed: 32660668
Cancer. 2021 Jun 1;127(11):1926-1932
pubmed: 33599303
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):335-337
pubmed: 32087098
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095
Ann Intern Med. 2020 Aug 4;173(3):240-242
pubmed: 32236490
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):699-704
pubmed: 32525856